Comparative Pharmacology
Head-to-head clinical analysis: AEROLATE versus AEROLATE SR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AEROLATE versus AEROLATE SR.
AEROLATE vs AEROLATE SR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Theophylline competitively inhibits phosphodiesterase, increasing cAMP levels, and acts as an adenosine receptor antagonist, leading to bronchodilation and reduced airway inflammation.
AEROLATE SR is a sustained-release formulation of theophylline, a methylxanthine bronchodilator. It acts by inhibiting phosphodiesterase (PDE) isoenzymes, leading to increased intracellular cyclic AMP (cAMP) levels. This results in relaxation of bronchial smooth muscle and suppression of the response of airways to stimuli. Theophylline also has anti-inflammatory effects, including inhibition of late-phase allergen-induced responses and reduction of eosinophil infiltration.
For asthma and COPD: 1-2 inhalations (90 mcg each) via metered-dose inhaler, 2 puffs twice daily, maximum 4 puffs twice daily. For acute exacerbations: 4-8 puffs every 20 minutes for up to 4 hours, then every 1-4 hours as needed.
400-800 mcg inhaled twice daily. For acute bronchospasm, 200-400 mcg as needed.
None Documented
None Documented
Terminal elimination half-life 12 hours; clinical context: q12h dosing achieves steady-state in 2-3 days
Terminal elimination half-life 12 hours (range 10–15 h) in adults; prolonged in hepatic impairment (up to 24 h) and elderly.
Renal (80% as unchanged drug), biliary/fecal (15% as metabolites), 5% other
Renal: 60% as unchanged drug; biliary/fecal: 30% as metabolites; 10% as unchanged in feces.
Category C
Category C
Bronchodilator
Bronchodilator